Ono Pharmaceutical (United States)

Recent papers from Ono Pharmaceutical (United States)

1. Preclinical pharmacokinetics and biodistribution of the dual adenosine A2A/A2B inhibitor muvadenant (M1069) in ratsXenobiotica · 2026
2. The SISAQOL-IMI glossary: harmonising terminology for patient-reported outcomes in cancer clinical trialsJournal of Patient-Reported Outcomes · 2026
3. Activated Platelets Express GPI-Anchored Fibrocystin-L (PKHD1L1), from Granules, Absent or Deficient in Paroxysmal Nocturnal HemoglobinuriaInternational Journal of Molecular Sciences · 2026
4. Could poultry vaccination reduce antimicrobial use and antimicrobial resistance in poultry in Ghana?World s Poultry Science Journal · 2026
5. Engineered strains as living factories: efficient biosynthesis and modification of natural products via synthetic biology and one-pot chemical tandem reactionsFrontiers in Microbiology · 2026
6. Elevating the Patient Voice in Early Phase Oncology Drug Development: The Value of Patient‐Reported Outcomes in Dosage Optimization Leveraging Clinical Pharmacology PrinciplesClinical Pharmacology & Therapeutics · 2026
7. Empowering Clinical Development With Disease Progression Modeling: Recommendations From the Clinical Trials Transformation InitiativeClinical and Translational Science · 2026
8. Sustainability in Pharmaceutical Research and Development: A Perspective on Opportunities for Clinical Pharmacology and Translational SciencesClinical Pharmacology & Therapeutics · 2026
9. Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responsesMolecular Therapy Oncology · 2026
10. Real‐World Use of Avelumab First‐Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and SafetyInternational Journal of Urology · 2026
11. IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphomaFuture Oncology · 2026
12. Efficacy and Safety of Crisugabalin in Patients With Moderate-to-Severe Central Neuropathic Pain: A Phase 3 Randomized Clinical Trial (LS2.006)Neurology · 2026
13. Design Synthesis and Evaluation of New Azole as Anti-fungal Agents2026
14. Human placental extract, melsmon, suppresses stress-induced neuroinflammation and peripheral inflammation in a mouse model of depressionFrontiers in Pharmacology · 2026
15. Comprehensive plasma-based epigenomic profiling from INTR@PID Lung 037 study samples to identify pathways associated with response and resistance to pembrolizumab in PD-L1–high NSCLC.Journal of Clinical Oncology · 2026
16. Plasma epigenomic profiling for identification of mechanisms of sensitivity, primary and acquired resistance to tepotinib in METex14 skipping metastatic NSCLC.Journal of Clinical Oncology · 2026
17. Outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC) by NECTIN4 and HER2 RNA expression: Exploratory analyses from JAVELIN Bladder 100.Journal of Clinical Oncology · 2026
18. A multi-axis biomarker model integrating KIM-1 and MAdCAM-1 in metastatic renal cell carcinoma.Journal of Clinical Oncology · 2026
19. Avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites.Journal of Clinical Oncology · 2026
20. Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple SclerosisNeurology Neuroimmunology & Neuroinflammation · 2026